脑肿瘤市场：依适应症、治疗类型、通路和地区划分

据估计，2026年脑肿瘤市值为47.614亿美元，预计到2033年将达到65.866亿美元。预计从2026年到2033年，其复合年增长率将达到8.3%。

全球脑瘤市场是肿瘤学领域最重要、最具挑战性的细分市场之一，涵盖多种起源于脑组织或从其他器官转移至脑部的恶性肿瘤。脑肿瘤，包括原发性肿瘤（如多形性胶质母细胞瘤、星状细胞瘤和少突胶质细胞瘤）以及转移性脑瘤，每年影响全球数十万名患者，由于血脑障壁和神经组织的脆弱性，其治疗面临着极其复杂的挑战。

该市场涵盖多种治疗方法，包括放射线治疗、化疗、标靶治疗和新型免疫疗法。製药公司、医疗设备製造商和生技公司都在研发方面投入大量资金，以满足尚未满足的医疗需求。全球脑肿瘤发生率的不断上升，加上人口老化、先进神经影像技术带来的诊断能力提升以及人们对早期检测意识的日益增强，使得该市场成为医疗创新的焦点，推动了对新型治疗方法和精准医疗策略的大量投资，旨在改善患者的治疗效果和生活品质。

市场动态

全球脑肿瘤市场受多种强劲的市场驱动因素推动，这些因素持续扩大市场机会并促进治疗方法的进步。主要市场驱动因素包括全球脑肿瘤发生率的上升，这归因于人口老化、环境暴露、遗传易感性以及诊断能力的提高，使得早期发现以往未确诊的病例成为可能。神经影像学、外科手术技术和放射治疗设备的创新，以及标靶治疗治疗和免疫疗法的研发，显着提高了治疗的准确性和有效性，透过改善患者预后和拓展治疗选择，推动了市场成长。

此外，製药公司在研发方面的巨额投资、不断上涨的医疗成本、日益扩大的公众意识宣传活动以及支持孤儿药研发的法规结构，都在加速新疗法的上市。然而，该市场也面临诸多限制因素，包括脑肿瘤的复杂性（由于血脑障壁的保护机制，脑肿瘤通常对传统疗法产生抗药性）、神经系统药物研发成本极高、监管核准过程严格、某些高度侵袭性肿瘤（例如多形性胶质母细胞瘤）的治疗选择有限，以及现有治疗方法带来的严重副作用会影响患者的生活品质。

此外，某些脑肿瘤亚型患者数量相对较少，给製药公司带来了商业性挑战；同时，医疗资源分配不均和治疗费用高昂限制了其在发展中地区的市场渗透。儘管面临这些挑战，但精准医疗技术的进步、能够有效穿过血脑障壁的新型药物递送系统的开发、免疫疗法的广泛应用、人工智能在诊断和治疗方案製定中的应用、联合治疗疗法的日益普及，以及学术机构、生物技术公司和大型製药公司之间合作的加强，都为脑肿瘤治疗领域的创新和新收入来源的创造提供了巨大的市场机会。

本次调查的主要特点。

• 本报告对全球脑肿瘤市场进行了详细分析，显示了以 2025 年为基准年，预测期（2026-2033 年）的市场规模和复合年增长率（%）。
• 此外，它还指出了每个细分市场的潜在商机，并说明了该市场中一个有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业所采取的竞争策略的关键见解。
• 本报告根据以下参数对全球脑肿瘤市场的主要企业参与者进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
• 本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 透过分析全球脑肿瘤市场时所使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监管与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 法规环境
• 产品上市及核准
• PEST分析
• 波特的分析
• 市场机会
• 法规环境
• 主要进展
• 产业趋势

第四章 全球脑瘤市场：依适应症划分，2021-2033年

• 脑膜瘤
• 胶质母细胞瘤
• 脑下垂体瘤
• 其他（寡树突胶质瘤、星状细胞瘤等）

第五章 全球脑瘤市场：依治疗类型划分，2021-2033年

• 化疗
• 标靶治疗
• 免疫疗法

第六章 全球脑肿瘤市场：依通路划分，2021-2033年

• 医院药房
• 零售药房
• 网路药房

第七章 全球脑肿瘤市场：依地区划分，2021-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第八章 竞争情势

• Novocure
• Servier
• Day One Biopharmaceuticals
• Jazz Pharmaceuticals
• Chimerix
• Novartis
• Roche
• Bayer
• AstraZeneca
• Merck &Co.
• Kazia Therapeutics
• CNS Pharmaceuticals
• Carthera
• Plus Therapeutics
• Genenta Science

第九章 分析师建议

• 机会
• 分析师意见
• Coherent Opportunity Map

第十章 参考文献与调查方法

• 参考
• 调查方法
• 关于本公司

Brain Cancer Market is estimated to be valued at USD 4,761.4 Mn in 2026 and is expected to reach USD 6,586.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.

Global brain cancer market represents one of the most critical and challenging segments within the oncology therapeutics landscape, encompassing a diverse array of malignant tumors that originate in brain tissue or spread to the brain from other organs. Brain cancers, including primary tumors such as glioblastoma multiforme, astrocytomas, oligodendrogliomas, and metastatic brain tumors, affect hundreds of thousands of patients worldwide annually, presenting significant therapeutic complexities due to the blood-brain barrier and the delicate nature of neurological tissue.

The market encompasses various treatment modalities including surgical interventions, radiation therapy, chemotherapy, targeted therapies, and emerging immunotherapeutic approaches, with pharmaceutical companies, medical device manufacturers, and biotechnology firms investing substantially in research and development to address the substantial unmet medical needs. The increasing incidence of brain cancers globally, coupled with aging populations, improved diagnostic capabilities through advanced neuroimaging technologies, and growing awareness about early detection, has positioned this market as a focal point for healthcare innovation, driving significant investments in novel therapeutic approaches and precision medicine strategies that aim to improve patient outcomes and quality of life.

Market Dynamics

The global brain cancer market is propelled by several compelling drivers that continue to expand market opportunities and therapeutic advancement. The primary market drivers include the rising global incidence of brain tumors attributed to factors such as aging demographics, environmental exposures, genetic predispositions, and improved diagnostic capabilities that enable earlier detection of previously undiagnosed cases. Technological innovations in neuroimaging, surgical techniques, radiation therapy equipment, and the development of targeted therapies and immunotherapies have significantly enhanced treatment precision and efficacy, driving market growth through improved patient outcomes and expanded treatment options.

Additionally, substantial investments in research and development by pharmaceutical companies, increased healthcare expenditure, growing awareness campaigns, and supportive regulatory frameworks for orphan drug development have accelerated the introduction of novel therapeutics into the market. However, the market faces significant restraints including the complex nature of brain cancers that often resist conventional treatments due to the blood-brain barrier's protective mechanism, extremely high research and development costs associated with neuropharmaceutical development, stringent regulatory approval processes, limited treatment options for certain aggressive tumor types like glioblastoma multiforme, and the substantial side effects associated with current treatment modalities that impact patient quality of life.

Furthermore, the relatively small patient populations for specific brain cancer subtypes present commercial challenges for pharmaceutical companies, while healthcare access disparities and high treatment costs limit market penetration in developing regions. Despite these challenges, the market presents substantial opportunities through the advancement of precision medicine approaches, development of novel drug delivery systems that can effectively cross the blood-brain barrier, expansion of immunotherapy applications, integration of artificial intelligence in diagnosis and treatment planning, growing emphasis on combination therapies, and increasing collaborative efforts between academic institutions, biotechnology companies, and pharmaceutical giants that are fostering innovation in brain cancer therapeutics and creating new revenue streams.

Key Features of the Study

• This report provides in-depth analysis of the global brain cancer market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global brain cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novocure, Servier, Day One Biopharmaceuticals, Jazz Pharmaceuticals, Chimerix, Novartis, Roche, Bayer, AstraZeneca, Merck & Co., Kazia Therapeutics, CNS Pharmaceuticals, Carthera, Plus Therapeutics, and Genenta Science
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global brain cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain cancer market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2021 - 2033)
  • Meningioma
  • Glioblastoma
  • Pituitary Tumors
  • Others (Oligodendroglioma, Astrocytoma, etc.)
• Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Chemotherapy
  • Carmustine
  • Temozolomide
  • Combination Drugs (Lomustine, Procarbazine, and Vincristine)
  • Targeted Therapy
  • Bevacizumab
  • Larotrectinib
  • Entrectinib
  • Others (Dinutuximab, Naxitamab-gqgk etc.)
  • Immunotherapy
  • Dostarlimab
  • Granulocyte-macrophage colony-stimulating factor
  • Pembrolizumab
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Novocure
  • Servier
  • Day One Biopharmaceuticals
  • Jazz Pharmaceuticals
  • Chimerix
  • Novartis
  • Roche
  • Bayer
  • AstraZeneca
  • Merck & Co.
  • Kazia Therapeutics
  • CNS Pharmaceuticals
  • Carthera
  • Plus Therapeutics
  • Genenta Science

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Brain Cancer Market, By Indication
  • Global Brain Cancer Market, By Treatment Type
  • Global Brain Cancer Market, By Distribution Channel
  • Global Brain Cancer Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trends

4. Global Brain Cancer Market, By Indication, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment
• Meningioma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Glioblastoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Pituitary Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Others (Oligodendroglioma, Astrocytoma, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Brain Cancer Market, By Treatment Type, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Carmustine
    • Temozolomide
    • Combination Drugs (Lomustine, Procarbazine, and Vincristine)
• Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Bevacizumab
    • Larotrectinib
    • Entrectinib
    • Others (Dinutuximab, Naxitamab-gqgk, etc.)
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Dostarlimab
    • Granulocyte-macrophage colony-stimulating factor
    • Pembrolizumab

6. Global Brain Cancer Market, By Distribution Channel, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Brain Cancer Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Novocure
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Servier
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Day One Biopharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Jazz Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Chimerix
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kazia Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CNS Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Carthera
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Plus Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genenta Science
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us